Enhanced Opioid Antagonist Delivery Systems
Legal Citation
Summary of the Inventive Concept
This inventive concept discloses improved opioid antagonist delivery systems, addressing the limitations of existing formulations and methods. The new systems provide enhanced bioavailability, rapid overdose rescue, and efficient treatment of alcohol dependence and constipation.
Background and Problem Solved
The original patent relates to compositions and methods for opioid antagonist delivery. However, the existing formulations have limitations, such as poor solubility, slow onset of action, and limited shelf-life. The new inventive concept addresses these limitations by introducing optimized pH levels, improved solubility profiles, and controlled-release formulations.
Detailed Description of the Inventive Concept
The inventive concept comprises five key aspects: 1) a system for opioid antagonist delivery featuring a portable injector and a formulation with an optimized pH level for enhanced bioavailability; 2) a method for rapid opioid overdose rescue using a parenteral formulation with an improved solubility profile; 3) a composition for treating alcohol dependence comprising a combination of an opioid antagonist and a mu-opioid receptor antagonist; 4) a drug delivery system for constipation treatment utilizing a controlled-release opioid antagonist formulation; and 5) a kit for pre-dosing a subject against opioid overdose comprising a parenteral formulation with an extended shelf-life and a user-friendly administration device.
Novelty and Inventive Step
The new claims introduce significant improvements over the original patent, including optimized pH levels, improved solubility profiles, and controlled-release formulations. These advancements provide enhanced bioavailability, rapid overdose rescue, and efficient treatment of alcohol dependence and constipation, which are not obvious from the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include different formulations, such as oral or transdermal delivery systems, or variations in the composition of the opioid antagonist and mu-opioid receptor antagonist. Additionally, the controlled-release formulation could be adapted for other indications, such as pain management or addiction treatment.
Potential Commercial Applications and Market
The enhanced opioid antagonist delivery systems have significant commercial potential in the pharmaceutical industry, particularly in the areas of overdose rescue, addiction treatment, and pain management. The target markets include hospitals, emergency responders, and healthcare providers, as well as individuals and families affected by opioid addiction.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulations, specifically opioid antagonist delivery systems, drug development, and parenteral drug delivery technologies
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist with expertise in drug formulation, pharmacokinetics, and parenteral drug delivery, holding at least a PhD or equivalent industrial experience in pharmaceutical sciences, with knowledge of opioid antagonist chemistry and delivery mechanisms
Obviousness Rationale
A person having ordinary skill in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core teachings about nalmefene formulations. The disclosed improvements in delivery systems, pH optimization, and combination therapies are logical progressions that would be apparent to a skilled pharmaceutical researcher exploring enhanced opioid antagonist delivery methods. The variations demonstrate incremental technical advancements that build directly upon the foundational pharmaceutical composition disclosed in the source patent.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,547 |
|---|---|
| Title | Compositions and methods for opioid antagonist delivery |
| Assignee(s) | Purdue Pharma L.P. |